Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999963878> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2999963878 abstract "ABSTRACT Background Four cycles of EP plus AHTRT is the standard treatment for LD-SCLC. IP demonstrated statistically significant overall survival (OS) improvement compared with EP for extensive-stage SCLC (JCOG9511; Noda et al., N Eng J Med, 2002). EP plus AHTRT followed by three cycles of IP is feasible with acceptable toxic effects for LD-SCLC (Kubota et al., CCR, 2005). Method Eligibility criteria included patients with previously untreated LD-SCLC with measurable lesion, ECOG PS of 0-1, age: ≤20, ≤70 years old. Eligible patients received one cycle of EP (etoposide 100 mg/m2 on days 1–3 and cisplatin 80 mg/m2 on day 1) plus AHTRT (1.5 Gy b.i.d. total 45 Gy/3 weeks). Patients who achieved CR, good PR, PR or SD with induction EP/AHTRT were randomized to receive either three cycles of consolidation EP or IP (irinotecan 60 mg/m2 and cisplatin 60 mg/m2 on days 1, 8, 15). Patients with CR or good PR after consolidation chemotherapy received prophylactic cranial irradiation. The primary end point is OS after the randomization. The planned sample size for randomization is 250 with a one-sided alpha of 2.5% and at least 70% power to detect a difference between groups, 30% in EP versus 42.5% in IP group in 3-year survival. Results From September 2002 to September 2006, 281 patients from 36 institutions were registered. After the induction EP/AHTRT, 258 patients were randomized to consolidation EP (n = 129) or IP (n = 129). Patient demographics were well balanced between the two groups. At the final analysis, the superiority of IP in OS was not demonstrated (hazard ratio of IP to EP, 1.085 [95% CI 0.80–1.46]; one-sided P = 0.70, stratified log-rank test). Median OS, 3-year survival and 5-year survival on EP were 3.2 years, 53% and 36%, versus 2.8 years, 47% and 34%, respectively (one-sided P = 0.7030). Median PFS on EP was 1.14 years and 1.03 years on IP (P = 0.7259). Grade 3/4 neutropenia (95%/78%), anemia (35%/39%), thrombocytopenia (21%/5%), neutropenic fever (17%/14%), diarrhea (2%/10%) were observed in EP and IP groups, respectively. Conclusion EP plus AHTRT followed by three cycles of IP failed to demonstrate survival advantage over four cycles of EP plus AHTRT which still is the standard treatment of LD-SCLC." @default.
- W2999963878 created "2020-01-23" @default.
- W2999963878 creator A5003703815 @default.
- W2999963878 creator A5017095102 @default.
- W2999963878 creator A5032337115 @default.
- W2999963878 creator A5034162457 @default.
- W2999963878 creator A5040839997 @default.
- W2999963878 creator A5047714811 @default.
- W2999963878 creator A5047834232 @default.
- W2999963878 creator A5050855780 @default.
- W2999963878 creator A5058549884 @default.
- W2999963878 creator A5065387771 @default.
- W2999963878 creator A5067304768 @default.
- W2999963878 creator A5071442298 @default.
- W2999963878 creator A5078287634 @default.
- W2999963878 creator A5086229141 @default.
- W2999963878 creator A5086351004 @default.
- W2999963878 date "2012-10-01" @default.
- W2999963878 modified "2023-09-28" @default.
- W2999963878 title "Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202" @default.
- W2999963878 doi "https://doi.org/10.1016/s0923-7534(20)31999-2" @default.
- W2999963878 hasPublicationYear "2012" @default.
- W2999963878 type Work @default.
- W2999963878 sameAs 2999963878 @default.
- W2999963878 citedByCount "0" @default.
- W2999963878 crossrefType "journal-article" @default.
- W2999963878 hasAuthorship W2999963878A5003703815 @default.
- W2999963878 hasAuthorship W2999963878A5017095102 @default.
- W2999963878 hasAuthorship W2999963878A5032337115 @default.
- W2999963878 hasAuthorship W2999963878A5034162457 @default.
- W2999963878 hasAuthorship W2999963878A5040839997 @default.
- W2999963878 hasAuthorship W2999963878A5047714811 @default.
- W2999963878 hasAuthorship W2999963878A5047834232 @default.
- W2999963878 hasAuthorship W2999963878A5050855780 @default.
- W2999963878 hasAuthorship W2999963878A5058549884 @default.
- W2999963878 hasAuthorship W2999963878A5065387771 @default.
- W2999963878 hasAuthorship W2999963878A5067304768 @default.
- W2999963878 hasAuthorship W2999963878A5071442298 @default.
- W2999963878 hasAuthorship W2999963878A5078287634 @default.
- W2999963878 hasAuthorship W2999963878A5086229141 @default.
- W2999963878 hasAuthorship W2999963878A5086351004 @default.
- W2999963878 hasBestOaLocation W29999638781 @default.
- W2999963878 hasConcept C121608353 @default.
- W2999963878 hasConcept C126322002 @default.
- W2999963878 hasConcept C126894567 @default.
- W2999963878 hasConcept C141071460 @default.
- W2999963878 hasConcept C168563851 @default.
- W2999963878 hasConcept C203092338 @default.
- W2999963878 hasConcept C204243189 @default.
- W2999963878 hasConcept C2776694085 @default.
- W2999963878 hasConcept C2778119113 @default.
- W2999963878 hasConcept C2778239845 @default.
- W2999963878 hasConcept C2780259306 @default.
- W2999963878 hasConcept C509974204 @default.
- W2999963878 hasConcept C526805850 @default.
- W2999963878 hasConcept C71924100 @default.
- W2999963878 hasConcept C90924648 @default.
- W2999963878 hasConceptScore W2999963878C121608353 @default.
- W2999963878 hasConceptScore W2999963878C126322002 @default.
- W2999963878 hasConceptScore W2999963878C126894567 @default.
- W2999963878 hasConceptScore W2999963878C141071460 @default.
- W2999963878 hasConceptScore W2999963878C168563851 @default.
- W2999963878 hasConceptScore W2999963878C203092338 @default.
- W2999963878 hasConceptScore W2999963878C204243189 @default.
- W2999963878 hasConceptScore W2999963878C2776694085 @default.
- W2999963878 hasConceptScore W2999963878C2778119113 @default.
- W2999963878 hasConceptScore W2999963878C2778239845 @default.
- W2999963878 hasConceptScore W2999963878C2780259306 @default.
- W2999963878 hasConceptScore W2999963878C509974204 @default.
- W2999963878 hasConceptScore W2999963878C526805850 @default.
- W2999963878 hasConceptScore W2999963878C71924100 @default.
- W2999963878 hasConceptScore W2999963878C90924648 @default.
- W2999963878 hasLocation W29999638781 @default.
- W2999963878 hasOpenAccess W2999963878 @default.
- W2999963878 hasPrimaryLocation W29999638781 @default.
- W2999963878 hasRelatedWork W1503024245 @default.
- W2999963878 hasRelatedWork W2006260103 @default.
- W2999963878 hasRelatedWork W2082547513 @default.
- W2999963878 hasRelatedWork W2098609854 @default.
- W2999963878 hasRelatedWork W2133266907 @default.
- W2999963878 hasRelatedWork W2135257379 @default.
- W2999963878 hasRelatedWork W2248341615 @default.
- W2999963878 hasRelatedWork W2348188253 @default.
- W2999963878 hasRelatedWork W2354631243 @default.
- W2999963878 hasRelatedWork W2598468315 @default.
- W2999963878 hasRelatedWork W2605054432 @default.
- W2999963878 hasRelatedWork W2790647466 @default.
- W2999963878 hasRelatedWork W2890799019 @default.
- W2999963878 hasRelatedWork W2999324305 @default.
- W2999963878 hasRelatedWork W3000340000 @default.
- W2999963878 hasRelatedWork W3000672011 @default.
- W2999963878 hasRelatedWork W3030586185 @default.
- W2999963878 hasRelatedWork W3209220541 @default.
- W2999963878 hasRelatedWork W582151643 @default.
- W2999963878 hasRelatedWork W2182135703 @default.
- W2999963878 isParatext "false" @default.
- W2999963878 isRetracted "false" @default.
- W2999963878 magId "2999963878" @default.
- W2999963878 workType "article" @default.